^
    2d
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    4d
    MZL-IIT-O: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL (clinicaltrials.gov)
    P2, N=30, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Inokai (orelabrutinib)
    7d
    Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2027 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Inokai (orelabrutinib)
    22d
    PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    1m
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=394, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P3 trial
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
    1m
    Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
    P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    1m
    A prospective observational study of Orelabrutinib combined with anti-CD20 monoclonal antibody followed by Orelabrutinib maintenance as first-line treatment for MZ (ChiCTR2500113665)
    P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    1m
    Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
    P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    1m
    Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (clinicaltrials.gov)
    P2, N=23, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib)
    1m
    Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma (clinicaltrials.gov)
    P4, N=88, Recruiting, Beijing Tongren Hospital
    New P4 trial
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
    2ms
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=990, Not yet recruiting, Zenas BioPharma (USA), LLC | N=330 --> 990
    Enrollment change
    |
    Inokai (orelabrutinib)
    2ms
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=330, Not yet recruiting, Zenas BioPharma (USA), LLC
    New P3 trial
    |
    Inokai (orelabrutinib)